Acción MOC MOLECURE S.A.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Molecure S.A.

Acciones

MOC

PLONCTH00011

Mercado cerrado - Warsaw S.E.
Otros sitios de cotización
 17:55:42 17/05/2024 		Varia. Cinco días. Varia. 1 de enero.
14,64 PLN -0,41 % Gráfico intradía de Molecure S.A. -5,06 % -24,92 %
17/05 Molecure S.A. presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
22/03 Molecure S.A. anuncia el primer paciente del estudio KITE de fase 2 de OATD-01 en sarcoidosis pulmonar CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01
Molecure S.A. announced that it has received PLN 49.968 million in funding
Poland's Molecure Files Investigational New Drug Application with US FDA for Pulmonary Sarcoidosis Drug
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
Poland's Molecure Doses First Patient in Cancer Treatment Trial
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer
Molecure S.A. Announces Management Changes
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
Molecure S.A.(WSE:MOC) dropped from S&P Global BMI Index
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción MOC
  4. Noticias Molecure S.A.
  5. Otros idiomas